The closing price of Edwards Lifesciences Corporation (NYSE: EW) was $84.74 for the day, down -4.96% from the previous closing price of $89.16. In other words, the price has decreased by -$4.42 from its previous closing price. On the day, 3061578 shares were traded. EW stock price reached its highest trading level at $89.14 during the session, while it also had its lowest trading level at $84.04.
Top 5 EV Tech Stocks to Buy for 2023
According a new report published by BloombergNEF on investment in the energy transition, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now.
Click Here to Download the FREE Report.
Our analysis of EW’s different ratios will help us gain a deeper understanding of the company. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 40.72 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 51.82. For the most recent quarter (mrq), Quick Ratio is recorded 2.20 and its Current Ratio is at 3.00. In the meantime, Its Debt-to-Equity ratio is 0.10 whereas as Long-Term Debt/Eq ratio is at 0.10.
Upgrades & Downgrades
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on May 10 when Ullem Scott B. sold 80,700 shares for $88.54 per share. The transaction valued at 7,145,004 led to the insider holds 18,294 shares of the business.
MUSSALLEM MICHAEL A sold 19,875 shares of EW for $1,758,653 on May 10. The Chairman & CEO now owns 81,725 shares after completing the transaction at $88.49 per share. On May 10, another insider, BOBO DONALD E JR, who serves as the CVP,Strategy/Corp Development of the company, sold 2,500 shares for $89.22 each. As a result, the insider received 223,050 and left with 33,078 shares of the company.
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, EW now has a Market Capitalization of 52.56B and an Enterprise Value of 51.99B. As of this moment, Edwards’s Price-to-Earnings (P/E) ratio for their current fiscal year is 35.26, and their Forward P/E ratio for the next fiscal year is 29.34. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 3.61. For the stock, the TTM Price-to-Sale (P/S) ratio is 9.28 while its Price-to-Book (P/B) ratio in mrq is 8.61. Its current Enterprise Value per Revenue stands at 9.45 whereas that against EBITDA is 29.27.
Stock Price History:
Over the past 52 weeks, EW has reached a high of $107.92, while it has fallen to a 52-week low of $67.13. The 50-Day Moving Average of the stock is 84.89, while the 200-Day Moving Average is calculated to be 82.43.
EW traded an average of 3.07M shares per day over the past three months and 2.26M shares per day over the past ten days. A total of 607.50M shares are outstanding, with a floating share count of 602.89M. Insiders hold about 0.10% of the company’s shares, while institutions hold 84.90% stake in the company. Shares short for EW as of Apr 27, 2023 were 9.18M with a Short Ratio of 9.18M, compared to 14.04M on Mar 30, 2023. Therefore, it implies a Short% of Shares Outstanding of 1.51% and a Short% of Float of 1.53%.
The firm’s stock currently is rated by 22 analysts. On average, analysts expect EPS of $0.65 for the current quarter, with a high estimate of $0.66 and a low estimate of $0.62, while EPS last year was $0.63. The consensus estimate for the next quarter is $0.63, with high estimates of $0.67 and low estimates of $0.58.
Analysts are recommending an EPS of between $2.6 and $2.43 for the fiscal current year, implying an average EPS of $2.55. EPS for the following year is $2.89, with 26 analysts recommending between $3.04 and $2.65.
It is expected that $90B in revenue will be generated in the current quarter, according to 19 analysts. It ranges from a high estimate of $1.53B to a low estimate of $1.47B. As of the current estimate, Edwards Lifesciences Corporation’s year-ago sales were $1.37B, an estimated increase of 9.30% from the year-ago figure. For the next quarter, 19 analysts are estimating revenue of $1.47B, an increase of 11.30% over than the figure of $9.30% in the same quarter last year. There is a high estimate of $1.53B for the next quarter, whereas the lowest estimate is $1.43B.
A total of 27 analysts have provided revenue estimates for EW’s current fiscal year. The highest revenue estimate was $6.08B, while the lowest revenue estimate was $5.83B, resulting in an average revenue estimate of $5.96B. In the same quarter a year ago, actual revenue was $5.38B, up 10.70% from the average estimate. Based on 27 analysts’ estimates, the company’s revenue will be $6.55B in the next fiscal year. The high estimate is $6.79B and the low estimate is $6.29B. The average revenue growth estimate for next year is up 10.00% from the average revenue estimate for this year.